262 related articles for article (PubMed ID: 22317852)
1. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis?
Pérez Campos D; Estévez Del Toro M; Peña Casanovas A; González Rojas PP; Morales Sánchez L; Gutiérrez Rojas AR
Reumatol Clin; 2012; 8(2):58-62. PubMed ID: 22317852
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up.
Tochimoto A; Kawaguchi Y; Hara M; Tateishi M; Fukasawa C; Takagi K; Nishimagi E; Ota Y; Katsumata Y; Gono T; Tanaka E; Yamanaka H
Mod Rheumatol; 2011 Jun; 21(3):296-301. PubMed ID: 21240620
[TBL] [Abstract][Full Text] [Related]
3. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
[TBL] [Abstract][Full Text] [Related]
5. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
6. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment.
Rojas-Serrano J; González-Velásquez E; Mejía M; Sánchez-Rodríguez A; Carrillo G
Reumatol Clin; 2012; 8(2):68-71. PubMed ID: 22341526
[TBL] [Abstract][Full Text] [Related]
7. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options for systemic sclerosis related interstitial lung diseases.
Mouthon L; Bérezné A; Guillevin L; Valeyre D
Respir Med; 2010 Jul; 104 Suppl 1():S59-69. PubMed ID: 20630349
[TBL] [Abstract][Full Text] [Related]
9. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study.
Kundu S; Paul S; Hariprasath K; Agarwal R; Ghosh S; Biswas D
Indian J Chest Dis Allied Sci; 2016; 58(1):7-10. PubMed ID: 28368564
[TBL] [Abstract][Full Text] [Related]
10. Scleroderma lung: pathogenesis, evaluation, and current therapy.
Co HT; Block JA; Sequeira W
Am J Ther; 2000 Sep; 7(5):321-4. PubMed ID: 11317180
[TBL] [Abstract][Full Text] [Related]
11. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.
Griffiths B; Miles S; Moss H; Robertson R; Veale D; Emery P
J Rheumatol; 2002 Nov; 29(11):2371-8. PubMed ID: 12415594
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.
Masui Y; Asano Y; Takahashi T; Shibata S; Akamata K; Aozasa N; Noda S; Taniguchi T; Ichimura Y; Toyama T; Tamaki Z; Sumida H; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
Mod Rheumatol; 2013 Mar; 23(2):323-9. PubMed ID: 22610787
[TBL] [Abstract][Full Text] [Related]
17. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases.
Takahashi T; Asano Y; Amiya E; Hatano M; Tamaki Z; Ozeki A; Watanabe A; Kawarasaki S; Nakao T; Taniguchi T; Ichimura Y; Toyama T; Watanabe M; Hirata Y; Nagai R; Sato S
Mod Rheumatol; 2012 Aug; 22(4):598-601. PubMed ID: 22015621
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.
Vanthuyne M; Blockmans D; Westhovens R; Roufosse F; Cogan E; Coche E; Nzeusseu Toukap A; Depresseux G; Houssiau FA
Clin Exp Rheumatol; 2007; 25(2):287-92. PubMed ID: 17543155
[TBL] [Abstract][Full Text] [Related]
19. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
20. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
